Key result
Anthracyclines and HER2 agents for breast cancer are linked to cardiotoxicity requiring multidisciplinary surveillance.
Why the study?
As breast cancer survival rates improve with advancing anticancer therapies, post-treatment health and quality of life have become significant concerns, particularly regarding treatment-related cardiotoxicity.
Personalized cardiovascular surveillance and a multidisciplinary approach are essential to mitigate the risk of therapy-related cardiotoxicity in breast cancer patients.
Supports integrated cardio-oncology care in breast cancer; leaves open optimal surveillance protocols for prospective trials.
The global incidence of breast cancer is on the rise, a trend also observed in South Korea. However, thanks to the rapid advancements in anticancer therapies, survival rates are improving. Consequently, post-treatment health and quality of life for breast cancer survivors are emerging as significant concerns, particularly regarding treatment-related cardiotoxicity. In this review, we delve into the cardiovascular complications associated with breast cancer treatment, explore surveillance protocols for early detection and diagnosis of late complications, and discuss protective strategies against cardiotoxicity in breast cancer patients undergoing anticancer therapy, drawing from multiple guidelines.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2024) conducted a review in Breast cancer and therapy-related cardiovascular toxicity. Anticancer therapies (anthracyclines, HER2-targeted agents, etc.) was evaluated. Anticancer therapies for breast cancer, particularly anthracyclines and HER2-targeted agents, are associated with significant cardiovascular toxicity, necessitating comprehensive risk assessment and multidisciplinary surveillance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: